Manhattan Behavioral Medicine | New York, NY

Research site
2 West 46th Street, Suite 405, New York, New York, United States of America
Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site


3 of 26
Status: Active
Trial type: Interventional
Funder type: Industry

A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy (VENTURA-2)

The purpose of this study is to evaluate the efficacy of aticaprant compared with placebo as adjunctive therapy to an antidepressant in improving dep...

Depressive Disorder, Major
Other: Placebo
Drug: Aticaprant

The purpose of this study is to assess the long-term safety and tolerability of aticaprant administered as adjunctive therapy to a current antidepres...

Depressive Disorder, Major
Drug: Aticaprant

This study is designed to evaluate safety and efficacy of fosgonimeton (ATH-1017) in the treatment of mild to moderate Alzheimer's disease with a ran...

Active, not recruiting
Alzheimer Disease
Dementia of Alzheimer Type
Drug: Placebo
Drug: ATH-1017

Trial conditions

Depression (13 trials)
Depressive Disorder (12 trials)
Major Depressive Disorder (12 trials)
Alzheimer Disease (5 trials)
Attention Deficit Disord... (2 trials)
Bipolar Disorder (2 trials)
Hyperkinesis (2 trials)
Anhedonia (1 trial)
Binge-Eating Disorder (1 trial)
Bulimia (1 trial)

And 8 more

Clinical trials

Find clinical trialsTrials by location


© Copyright 2024 Veeva Systems